Drugmaker Supernus Pharmaceuticals said on Monday it will acquire Sage Therapeutics , which makes treatments for neurological conditions, in a deal worth up to $795 million.
ROCKVILLE, Md. and CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a definitive agreement
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company") is pleased to announce that, due to continued and signific
PHILADELPHIA, PA / ACCESS Newswire / June 9, 2025 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Sage Therapeutics, Inc. (NASDAQ:SAGE) ("Sage
Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company") is pleased to announce that, further to its May 9 and May

Sage Potash Announces Financing Update

04:00pm, Tuesday, 27'th May 2025
Vancouver, British Columbia--(Newsfile Corp. - May 27, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company") announces that, further to its May 9, 2025 news release, i
Sage Group (SGPYY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company") announces shares for debt transactions for an aggregate of
The Sage Group plc (OTCPK:SGGEF) Q2 2025 Earnings Call Transcript May 15, 2025 3:30 AM ET Company Participants Steve Hare - Chief Executive Officer Jonathan Howell - Chief Financial Officer Conference
The Sage Group PLC (LSE:SGE) shares fell 4.5% on Thursday morning after the accountancy software group published half-year results that seemed to be in-line or ahead of City forecasts.  An existing

Sage Potash Announces Financing

09:41pm, Friday, 09'th May 2025
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company") is pleased to announce a non-brokered private placement of
SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. “We delivered strong g
NEW YORK , April 22, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sage Therapeutics, Inc. (NASDAQ: SAGE)  breach
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2025) - Sage Potash Corp. (TSXV: SAGE) (OTCQB: SGPTF) ("Sage Potash" or the "Company") is pleased to announce the appointment of Tim Mizuno as
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE